Cobimetinib plus atezolizumab for <i>RAS</i> and <i>NF</i>1/2-mutated poorly differentiated thyroid carcinoma.
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center), Brian McKinley(The University of Texas MD Anderson Cancer Center), Dzifa Y. Duose(The University of Texas MD Anderson Cancer Center), Matthew S. Ning(The University of Texas MD Anderson Cancer Center), Maria Gule-Monroe(The University of Texas MD Anderson Cancer Center), Suyu Liu(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Mark E. Zafereo(The University of Texas MD Anderson Cancer Center)
Cited by 4
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231